Genomic Correlates of Response to Everolimus in Aggressive Radioiodine-refractory Thyroid Cancer: A Phase II StudyGlenn J. Hanna, Jochen H. Lorch, Antonio Calles et al.|Clinical Cancer Research|2018Cited by 125
Malignant struma ovariiLeila Yassa, Ellen Marqusee, Peter M. Sadow|Nature Clinical Practice Endocrinology & Metabolism|2008Cited by 115
A phase II study of nivolumab (N) plus ipilimumab (I) in radioidine refractory differentiated thyroid cancer (RAIR DTC) with exploratory cohorts in anaplastic (ATC) and medullary thyroid cancer (MTC).Jochen H. Lorch, David A. Barbie, Justine A. Barletta et al.|Journal of Clinical Oncology|2020Cited by 65